Company Profile

ISTO Biologics Inc (AKA:ISTO Technologies, Inc)
Profile last edited on: 3/14/2019            CAGE: 4LKQ3

Orthobiologics: regenerating and restoring function to damaged cartilage and bone.
Year Founded
1997
1st Award Year
1999
Latest Award
2017
Program Status
Active (Acquired)
Popularity Index

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1155 Olivette Executive Parkway Suite 200
St Louis, MO 63132
   (314) 995-6049
   info@istotech.com
   www.istotech.com
Multiple Locations:   
Congressional District:   01
County:   St. Louis

Public Profile

ISTO Biologics, Inc., was acquired by Thompson Street Capital Partners in June 2016 but went on to institute a working relationship with Zimmer an important player in the orthopaedic reconstructive implants and fracture management products but its first foray into orthobiolgics. ISTO Biologics - the entity created when Arteriocyte and Isto Technol0gies - both SBIR involved - merged in 2016 - is an orthobiologics company developing diffentiated products for spinal therapy, sports medicine, and trauma. The firm develops implantable biomaterials for the repair and regeneration of musculoskeletal tissues, such as bone and cartilage - being developed to grow human cartilage tissue from chondrocytes derived from human donors. This laboratory-grown cartilage is intended for surgical implantation to repair or replace injured or diseased cartilage in the knee or other joints which has, until now, been unreplaceable. ISTO is also developing a cell-based regenerative therapy for spinal discs. The firm offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. Two of its products are currently undergoing clinical trials.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
25-49
Revenue Range
2.5M-5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2017 2 NIH $1,543,518
Biomaterial Augmented Microfracture Repair of Full-Thickness Chondral Defects04
2003 2 NIH $839,955
Effect of Culture Conditions on Neocartilage Properties

Key People / Management

  George Dunbar -- President And Chief Executive Officer

  Joseph Feder -- Co-Founder and Chairman, Former President and CEO

  Phillip Kuhn -- Chief Commerical Officer

  Mitchell Seyedin -- Executive Chairman

  Anthony John Ward